SARCOMA CLINICAL TRIAL FUNDED BY STAND UP TO CANCER REDUCES RISK OF RELAPSE BY 43%
/PRNewswire/ -- For the last three decades, breakthroughs have been sparse for soft tissue sarcomas, which are rare cancers that affect muscles, fat and other...
Stay updated with breaking news from Scientific Partner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- For the last three decades, breakthroughs have been sparse for soft tissue sarcomas, which are rare cancers that affect muscles, fat and other...
Chimeric Antigen Receptors (CARs) have opened up an exciting new field of therapeutic advancements for rare and difficult-to-treat cancers, as they have the ability to deliver targeted therapies that can kill tumor cells.
The Bristol Myers Squibb Foundation (BMS Foundation), together with Virginia Commonwealth University (VCU), the American Association for Cancer Research (AACR), Gilead Sciences, Inc., and Amgen today announced that an additional 65 physicians have been selected to receive the Robert A. Winn Diversity in Clinical ...
65 physicians comprise Cohort III, bringing the total to 179 participants in the program’s third year ...
The Bristol Myers Squibb Foundation (BMS Foundation), together with Virginia Commonwealth University (VCU), the American Association for Cancer Research (AACR), Gilead Sciences, Inc., and Amgen today announced that an additional 65 physicians have...